Inflammation and peripheral arterial disease: The value of circulating biomarkers (Review)
- Authors:
- Salvatore Santo Signorelli
- Valerio Fiore
- Grazia Malaponte
-
Affiliations: Department of Medical and Pediatric Sciences, Medical Angiology Unit, University of Catania, Catania, Italy, Department of Bio-medical Sciences, General Pathology and Oncology Section, University of Catania, Catania, Italy - Published online on: February 13, 2014 https://doi.org/10.3892/ijmm.2014.1657
- Pages: 777-783
This article is mentioned in:
Abstract
|
Norgern L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA and Fowkes FG; TASC II Working Group. Inter-society consensus for management of peripheral arterial diseases (TASCII). J Vasc Surg. 45(Suppl S): S5–S67. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Brodie BC: Lectures illustrative of various subjects in pathology and surgery. London: A Spottiswoode; 1846 | |
|
Charcot JMC: Sur la claudication intermittente observe dans un cas d’obliteration complete de l’ une des arteres iliaques primitives. CR Soc Biol (Paris). 5:2251858. | |
|
Stammers FA: Peripheral arterial disease; some points of common interest to general and orthopaedic surgery. J Bone Joint Surg Br. 36-B:209–217. 1954.PubMed/NCBI | |
|
Allen EV, Barker NW and Hines EA: Peripheral Vascular Diseases. 1st edition. W.B. Saunders, Co; Philadelphia, PA: pp. 343–401. 1946 | |
|
O’Riordain DS and O’Donnell JA: Realistic expectations for the patient with intermittent claudication. Br J Surg. 78:861–863. 1991.PubMed/NCBI | |
|
Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ and Browner D: Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 326:381–386. 1992.PubMed/NCBI | |
|
Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E and Ruckley CV: Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 25:1172–1181. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Brevetti G, Martone VD, Perna S, Cacciatore F, Corrado S, Di Donato A and Di Iorio A: Intermittent claudication and risk of cardiovascular events. Angiology. 49:843–848. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Brevetti G, Schiano V, Verdoliva S, Silvestro A, Sirico G, De Maio J, Lanero S and Chiariello M: Peripheral arterial disease and cardiovascular risk in Italy. Results of the Peripheral Arteriopathy and Cardiovascular Events (PACE) study. J Cardiovasc Med (Hagerstown). 7:608–613. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ridker PM: Are associations between infection and coronary disease causal or due to confounding? Am J Med. 106:376–377. 1999.PubMed/NCBI | |
|
Mendez MV, Scott T, LaMorte W, Vokonas P, Menzoian JO and Garcia R: An association between periodontal disease and peripheral vascular disease. Am J Surg. 176:153–157. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Hung HC, Willett W, Merchant A, Rosner BA, Ascherio A and Joshipura KJ: Oral health and peripheral arterial disease. Circulation. 107:1152–1157. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Wiesli P and Schulthess G: Effect of roxithromycin treatment on the endothelial function of Chlamydia pneumoniae seropositive men suffering from peripheral arterial occlusive disease. Circulation. 106:e2262002.PubMed/NCBI | |
|
Wiesli P, Czerwenka W, Meniconi A, Maly FE, Hoffmann U, Vetter W and Schulthess G: Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation. 105:2646–2652. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Krayenbuehl PA, Wiesli P, Maly FE, Vetter W and Schulthess G: Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment. Atherosclerosis. 179:103–110. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Vance DE and Van den Bosch H: Cholesterol in the year 2000. Biochim Biophys Acta. 1529:1–8. 2000.PubMed/NCBI | |
|
Hodgson JA: Treatise on the Diseases of Arteries and Veins. Thomas Underwood; London, UK: 1815 | |
|
Virchow R: Cellular Pathology. John Churchill; London, UK: 1858 | |
|
Osler W: Diseases of the arteries. Modern Medicine: Its Practice and Theory. Lea and Febiger; Philadelphia, PA: pp. 429–447. 1908 | |
|
Ross: Atherosclerosis - an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar | |
|
Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation. 105:1135–1143. 2002. View Article : Google Scholar | |
|
Brevetti G, Schiano V and Chiariello M: Endothelial dysfunction: a key to the pathophysiology and natural history of peripheral arterial disease? Atherosclerosis. 197:1–11. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ridker PM, Cushman M, Stampfer MJ, Tracy RP and Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 97:425–428. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Bloemenkamp DG, van den Bosch MA, Mali WP, Tanis BC, Rosendaal FR, Kemmeren JM, Algra A, Visseren FL and van der Graaf Y: Novel risk factors for peripheral arterial disease in young women. Am J Med. 113:462–467. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Pradhan AD, Rifai N and Ridker PM: Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation. 106:820–825. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Brevetti G, Oliva G, Silvestro A, Scopacasa F and Chiariello M; Peripheral Arteriopathy and Cardiovascular Events (PACE) Study Group. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. Atherosclerosis. 175:131–138. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K and He J: Relation of inflammation to peripheral arterial disease in the National Health and Nutrition Examination Survey, 1999–2002. Am J Cardiol. 96:1579–1583. 2005. | |
|
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD and Fowkes FG: C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation. 112:976–983. 2005. View Article : Google Scholar | |
|
Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR and Ballantyne CM: Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 183:301–307. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Cassar K, Bachoo P, Ford I, Greaves M and Brittenden J: Markers of coagulation activation, endothelial stimulation and inflammation in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 29:171–176. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD and Fowkes FG: Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 28:354–362. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ and Ruckley CV: Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 135:331–340. 1992. | |
|
Murabito JM, D’Agostino RB, Silbershatz H and Wilson WF: Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation. 96:44–49. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Pryor WA and Stone K: Oxidants in cigarette smoke: radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann NY Acad Sci. 686:12–27. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JA and Roberts LJ II: Increase in circulating products of lipid perioxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med. 332:1198–1203. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Baynes JW and Thorpe SR: Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 48:1–9. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Rahman I and Adcock IM: Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 28:219–242. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM and Hiatt WR: Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 286:1317–1324. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Griendling KK, Ushio-Fukai M, Lassegue B and Alexander RW: Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension. 29:366–373. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P and Kubler W: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 19:1623–1629. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M and Egido J: Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 95:1532–1541. 1997. View Article : Google Scholar | |
|
Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG and Medford RM: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation. 100:1223–1229. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ and Fogelman AM: Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 87:5134–5138. 1990. View Article : Google Scholar | |
|
Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM and Lusis AJ: Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 344:254–257. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Li JJ and Fang CH: C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Med Hypotheses. 62:499–506. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Galkina E and Ley K: Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. 27:2292–2301. 2007. View Article : Google Scholar | |
|
Tedgui A and Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 86:515–581. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Braunersreuther V, Mach F and Steffens S: The specific role of chemokines in atherosclerosis. Thromb Haemost. 97:714–721. 2007.PubMed/NCBI | |
|
Roldan V, Marin F, Lip GY and Blann AD: Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost. 90:1007–1020. 2003.PubMed/NCBI | |
|
Nielsen LB: Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. Atherosclerosis. 143:229–243. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Carmelli D, Fabsitz RR, Swan GE, Reed T, Miller B and Wolf PA: Contribution of genetic and environmental influences to ankle-brachial blood pressure index in the NHLBI Twin Study. National Heart, Lung, and Blood Institute. Am J Epidemiol. 151:452–458. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas JC, Vohra RS, Beer S, Bhatti K, Ponnambalam S and Homer-Vanniasinkam S: Biomarkers in peripheral arterial disease. Trends Cardiovasc Med. 19:147–151. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fiessinger JN and Schäfer M: Trial of iloprost versus aspirin treatmentfor critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet. 335:555–557. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Dormandy J: Use of the prostacyclin analogue iloprost in the treatment of patients with critical limb ischaemia. Therapie. 46:319–322. 1991.PubMed/NCBI | |
|
Lessiani G, Vazzana N, Cuccurullo C, Di Michele D, Laurora G, Sgrò G, Di Ruscio P, Simeone E, Di Iorio P, Lattanzio S, Liani R, Ferrante E and Davì G: Inflammation, oxidative stress and platelet activation in aspirin-treated critical limb ischaemia: beneficial effects of iloprost. Thromb Haemost. 105:321–328. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Miyashita Y, Saito S, Miyamoto A, Iida O and Nanto S: Cilostazol increases skin perfusion pressure in severely ischemic limbs. Angiology. 62:15–17. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shalhoub J, Davies AH and Franklin IJ: Cilostazol may improve outcome in critical limb ischemia. Int Angiol. 28:363–366. 2009.PubMed/NCBI | |
|
Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E and Wahlberg E: A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 45:1185–1191. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Folsom AR, Pankow JS, Tracy RP, Arnett DK, Peacock JM, Hong Y, Djoussé L and Eckfeldt JH; Investigators of the NHBLI Family Heart Study. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol. 88:112–117. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Galis ZS and Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 90:251–262. 2002.PubMed/NCBI | |
|
Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM and Ivan E: Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 91:852–859. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Galis ZS, Sukhova GK, Lark MW and Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 94:2493–2503. 1994. View Article : Google Scholar | |
|
Indelicato M, Navolanic PM, Pennisi G and Mazzarino MC: Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc Med. 10:1–6. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ley K: The role of selectins in inflammation and disease. Trends Mol Med. 9:263–268. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Boulbou MS, Koukoulis GN, Vasiou KG, Petinaki EA, Gourgoulianis KI and Fezoulidis IB: Increased soluble E-selectin levels in type 2 diabetic patients with peripheral arterial disease. Int Angiol. 23:18–24. 2004.PubMed/NCBI | |
|
Signorelli SS, Mazzarino MC, Di Pino L, Malaponte G, Porto C, Pennisi G, Marchese G, Costa MP, Digrandi D, Celotta G and Virgilio V: High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med. 8:15–19. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Flex A, Gaetani E, Angelini F, Sabusco A, Chillà C, Straface G, Biscetti F, Pola P, Castellot JJ Jr and Pola R: Pro-inflammatory genetic profiles in subjects with peripheral arterial occlusive disease and critical limb ischemia. J Intern Med. 262:124–130. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Merten M and Thiagarajan P: P-selectin in arterial thrombosis. Z Kardiol. 93:855–863. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, White DB and Commerota AJ: Effect of antiplateletagents clopidogrel, aspirin and cilastazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost. 96:738–743. 2006.PubMed/NCBI | |
|
Dinarello CA: Blocking interleukin-1β in acute and chronic autoinflammatory diseases. J Intern Med. 269:16–28. 2011. | |
|
Dinarello CA: IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 103:11–24. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Saetre T, Enoksen E, Lyberg T, Stranden E, Jørgensen JJ, Sundhagen JO and Hisdal J: Supervised exercise training reduces plasma levels of the endothelial inflammatory markers E-selectin and ICAM-I in patients with peripheral arterial disease. Angiology. 62:301–305. 2011. View Article : Google Scholar | |
|
Libby P, Sukhova G, Lee RT and Galis ZS: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol. 25(Suppl 2): S9–S12. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Fiotti N, Giansante C, Ponte E, Delbello C, Calabrese S, Zacchi T, Dobrina A and Guarnieri G: Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis. 145:51–60. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
McDermott MM, Guralnik JM, Corsi A, Albay M, Macchi C, Bandinelli S and Ferrucci L: Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J. 150:276–281. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Dinarello CA: Interleukin-1. Cytokine Growth Factor Rev. 8:253–265. 1997. View Article : Google Scholar | |
|
Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D and Musikic P: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41:2196–2204. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Malek TR and Castro I: Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 33:153–165. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lindholt JS and Shi GP: Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 31:453–463. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wan YY and Flavell RA: The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev. 212:114–130. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Khew-Goodall Y, Wadham C, Stein BN, Gamble JR and Vadas MA: Stat6 activation is essential for interleukin-4 induction of P-selectin transcription in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol. 19:1421–1429. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Depalma RG, Hayes VW, Chow BK, Shamayevu G, May PE and Zackarski LR: Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial. J Vasc Surg. 51:1498–1503. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nylaende M, Kroese A, Stranden E, Morken B, Sandbaek G, Lindahl AK, Arnesen H and Seljeflot I: Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med. 11:21–28. 2006. View Article : Google Scholar | |
|
McDermott MM, Liu K, Ferrucci L, Tian L, Guralnik JM, Tao H, Ridker PM and Criqui MH: Relation of interleukin-6 and vascular cellular adhesion molecule-1 levels to functional decline in patients with lower extremity peripheral arterial disease. Am J Cardiol. 107:1392–1398. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Akira S, Taga T and Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol. 54:1–78. 1993. View Article : Google Scholar | |
|
Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K and Geginat J: Biology of interleukin-10. Cytokine Growth Factor Rev. 21:331–344. 2010. View Article : Google Scholar | |
|
Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino MC and Malaponte G: Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol. 59:211–215. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Marino F, Guasti L, Tozzi M, Consuelo Maio R, Castiglioni L, Rasini E, Schembri L, Maroni L, Legnaro M, De Leo A, Piffaretti G, Castelli P, Venco A, Lecchini S and Cosentino M: Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease. J Cardiovasc Pharmacol. 54:520–525. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D and Tedgui A: Protective role of interleukin-10 in atherosclerosis. Circ Res. 85:e17–e24. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Mallat Z, Heymes C, Ohan J, Faggin E, Leseche G and Tedgui A: Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol. 19:611–616. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O, Perret C, Münzel T, Rupprecht HJ, Lackner K, Cambien F and Blankenberg S; AtheroGene Investigators. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 112:643–650. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Anguera I, Miranda-Guardiola F, Bosch X, Filella X, Sitges M, Marín JL, Betriu A and Sanz G: Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J. 144:811–817. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Smith DA, Irving SD, Sheldon J, Cole D and Kaski JC: Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 104:746–749. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Blanco E, Moñux G, Mas A, Serrano FJ, de la Concha EG and Urcelay E: Role of IL-10 promoter polymorphisms in the development of severe aorto-iliac occlusive disease. Hum Immunol. 69:651–654. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML and Zeiher AM; CAPTURE Study Investigators. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 107:2109–2114. 2003. View Article : Google Scholar |
